Tejas Savant
Stock Analyst at Morgan Stanley
(2.33)
# 1,416
Out of 4,479 analysts
180
Total ratings
41.6%
Success rate
-2.43%
Average return
Main Sectors:
26 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AKYA Akoya Biosciences | Maintains: Overweight | $8 → $4 | $2.21 | +81.00% | 9 | Jun 3, 2024 | |
| PACB Pacific Biosciences of California | Maintains: Equal-Weight | $10 → $4 | $1.20 | +233.33% | 7 | May 15, 2024 | |
| DNA Ginkgo Bioworks Holdings | Maintains: Equal-Weight | $2 → $1 | $0.32 | +209.41% | 2 | May 15, 2024 | |
| OLK Olink Holding AB (publ) | Maintains: Equal-Weight | $26 | $25.55 | +1.76% | 11 | Mar 26, 2024 | |
| VCYT Veracyte | Maintains: Underweight | $22 → $21 | $21.33 | -1.55% | 7 | Feb 26, 2024 | |
| HOLX Hologic | Maintains: Equal-Weight | $86 → $82 | $74.10 | +10.66% | 7 | Nov 13, 2023 | |
| NTRA Natera | Maintains: Overweight | $70 → $68 | $107.81 | -36.93% | 7 | Nov 10, 2023 | |
| MRVI Maravai LifeSciences Holdings | Maintains: Overweight | $12 → $11 | $6.94 | +58.50% | 10 | Nov 9, 2023 | |
| CTKB Cytek Biosciences | Maintains: Equal-Weight | $8 → $7 | $5.61 | +24.78% | 8 | Nov 9, 2023 | |
| NEO NeoGenomics | Maintains: Equal-Weight | $16 → $17 | $13.93 | +22.04% | 11 | Nov 8, 2023 | |
| IQV IQVIA Holdings | Maintains: Overweight | $240 → $225 | $208.49 | +7.92% | 8 | Nov 3, 2023 | |
| AVTR Avantor | Maintains: Overweight | $24 → $22 | $20.77 | +5.92% | 12 | Oct 30, 2023 | |
| TMO Thermo Fisher | Maintains: Overweight | $600 → $545 | $541.72 | +0.61% | 9 | Oct 26, 2023 | |
| ADPT Adaptive Biotechnologies | Maintains: Equal-Weight | $13 → $10 | $3.60 | +177.78% | 9 | Oct 24, 2023 | |
| CTLT Catalent | Maintains: Overweight | $52 → $55 | $56.16 | -2.07% | 10 | Aug 30, 2023 | |
| CYRX Cryoport | Initiates: Equal-Weight | $16 | $6.39 | +150.39% | 1 | Aug 17, 2023 | |
| TXG 10x Genomics | Reiterates: Overweight | $65 | $18.59 | +249.65% | 8 | Aug 7, 2023 | |
| NAUT Nautilus Biotechnology | Reiterates: Equal-Weight | $6 | $2.27 | +164.32% | 3 | Aug 3, 2023 | |
| SOPH SOPHiA GENETICS | Maintains: Overweight | $11 → $10 | $4.64 | +115.52% | 8 | May 10, 2023 | |
| RPID Rapid Micro Biosystems | Reiterates: Equal-Weight | $2.75 | $0.68 | +304.35% | 5 | Mar 7, 2023 | |
| PSNL Personalis | Maintains: Equal-Weight | $11 → $5 | $1.20 | +318.41% | 4 | Feb 27, 2023 | |
| SEER Seer, Inc. | Maintains: Equal-Weight | $11 → $10 | $1.69 | +491.72% | 9 | Feb 21, 2023 | |
| GH Guardant Health | Maintains: Overweight | $80 → $73 | $28.26 | +158.32% | 7 | Feb 21, 2023 | |
| ILMN Illumina | Maintains: Equal-Weight | $240 → $225 | $105.50 | +113.27% | 4 | Nov 7, 2022 | |
| CRL Charles River Laboratories International | Downgrades: Equal-Weight | $350 → $250 | $203.24 | +23.01% | 1 | Aug 4, 2022 | |
| BDSX Biodesix | Maintains: Equal-Weight | $7 → $5 | $1.53 | +226.80% | 3 | May 12, 2022 |
Akoya Biosciences
Jun 3, 2024
Maintains: Overweight
Price Target: $8 → $4
Current: $2.21
Upside: +81.00%
Pacific Biosciences of California
May 15, 2024
Maintains: Equal-Weight
Price Target: $10 → $4
Current: $1.20
Upside: +233.33%
Ginkgo Bioworks Holdings
May 15, 2024
Maintains: Equal-Weight
Price Target: $2 → $1
Current: $0.32
Upside: +209.41%
Olink Holding AB (publ)
Mar 26, 2024
Maintains: Equal-Weight
Price Target: $26
Current: $25.55
Upside: +1.76%
Veracyte
Feb 26, 2024
Maintains: Underweight
Price Target: $22 → $21
Current: $21.33
Upside: -1.55%
Hologic
Nov 13, 2023
Maintains: Equal-Weight
Price Target: $86 → $82
Current: $74.10
Upside: +10.66%
Natera
Nov 10, 2023
Maintains: Overweight
Price Target: $70 → $68
Current: $107.81
Upside: -36.93%
Maravai LifeSciences Holdings
Nov 9, 2023
Maintains: Overweight
Price Target: $12 → $11
Current: $6.94
Upside: +58.50%
Cytek Biosciences
Nov 9, 2023
Maintains: Equal-Weight
Price Target: $8 → $7
Current: $5.61
Upside: +24.78%
NeoGenomics
Nov 8, 2023
Maintains: Equal-Weight
Price Target: $16 → $17
Current: $13.93
Upside: +22.04%
IQVIA Holdings
Nov 3, 2023
Maintains: Overweight
Price Target: $240 → $225
Current: $208.49
Upside: +7.92%
Avantor
Oct 30, 2023
Maintains: Overweight
Price Target: $24 → $22
Current: $20.77
Upside: +5.92%
Thermo Fisher
Oct 26, 2023
Maintains: Overweight
Price Target: $600 → $545
Current: $541.72
Upside: +0.61%
Adaptive Biotechnologies
Oct 24, 2023
Maintains: Equal-Weight
Price Target: $13 → $10
Current: $3.60
Upside: +177.78%
Catalent
Aug 30, 2023
Maintains: Overweight
Price Target: $52 → $55
Current: $56.16
Upside: -2.07%
Cryoport
Aug 17, 2023
Initiates: Equal-Weight
Price Target: $16
Current: $6.39
Upside: +150.39%
10x Genomics
Aug 7, 2023
Reiterates: Overweight
Price Target: $65
Current: $18.59
Upside: +249.65%
Nautilus Biotechnology
Aug 3, 2023
Reiterates: Equal-Weight
Price Target: $6
Current: $2.27
Upside: +164.32%
SOPHiA GENETICS
May 10, 2023
Maintains: Overweight
Price Target: $11 → $10
Current: $4.64
Upside: +115.52%
Rapid Micro Biosystems
Mar 7, 2023
Reiterates: Equal-Weight
Price Target: $2.75
Current: $0.68
Upside: +304.35%
Personalis
Feb 27, 2023
Maintains: Equal-Weight
Price Target: $11 → $5
Current: $1.20
Upside: +318.41%
Seer, Inc.
Feb 21, 2023
Maintains: Equal-Weight
Price Target: $11 → $10
Current: $1.69
Upside: +491.72%
Guardant Health
Feb 21, 2023
Maintains: Overweight
Price Target: $80 → $73
Current: $28.26
Upside: +158.32%
Illumina
Nov 7, 2022
Maintains: Equal-Weight
Price Target: $240 → $225
Current: $105.50
Upside: +113.27%
Charles River Laboratories International
Aug 4, 2022
Downgrades: Equal-Weight
Price Target: $350 → $250
Current: $203.24
Upside: +23.01%
Biodesix
May 12, 2022
Maintains: Equal-Weight
Price Target: $7 → $5
Current: $1.53
Upside: +226.80%